Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
NMRA 
Neumora Therapeutics, Inc. (NMRA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: NMRA (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $7
1 Year Target Price $7
| 1 | Strong Buy |
| 2 | Buy |
| 5 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -12.59% | Avg. Invested days 26 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 242.92M USD | Price to earnings Ratio - | 1Y Target Price 7 |
Price to earnings Ratio - | 1Y Target Price 7 | ||
Volume (30-day avg) 8 | Beta - | 52 Weeks Range 0.61 - 17.19 | Updated Date 09/17/2025 |
52 Weeks Range 0.61 - 17.19 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.57 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -52.63% | Return on Equity (TTM) -89.37% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 45291140 | Price to Sales(TTM) - |
Enterprise Value 45291140 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -4.65 | Shares Outstanding 161945427 | Shares Floating 86062658 |
Shares Outstanding 161945427 | Shares Floating 86062658 | ||
Percent Insiders 27.53 | Percent Institutions 54.79 |
Upturn AI SWOT
Neumora Therapeutics, Inc.
Company Overview
History and Background
Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded in 2019. It focuses on developing novel therapeutics for brain diseases. Significant milestones include securing funding, advancing drug candidates through clinical trials, and going public in 2023.
Core Business Areas
- Neuromodulation Therapies: Development of therapies targeting neuronal circuits and brain activity.
- Precision Medicine: Utilizing biomarkers and genetics to identify patient populations most likely to respond to treatments.
- Clinical Development: Conducting clinical trials to evaluate the safety and efficacy of drug candidates.
Leadership and Structure
The company is led by a management team with experience in neuroscience and drug development. The organizational structure includes research, clinical development, and commercial functions.
Top Products and Market Share
Key Offerings
- Navacaprant: An investigational kappa opioid receptor (KOR) antagonist in Phase 3 development for Major Depressive Disorder (MDD). No current market share yet as it is still in clinical trials. Competitors include existing antidepressants like SSRIs (e.g., Prozac, Zoloft) and other novel antidepressant therapies under development.
- NMRA-266: A selective vasopressin 1A receptor (V1AR) antagonist in Phase 1 development for Social Anxiety Disorder (SAD). No current market share yet as it is still in clinical trials. Competitors include SSRIs/SNRIs and other anxiolytics like benzodiazepines.
- NMRA-511: A novel clinical-stage development program for Huntington's Disease (HD). No current market share yet as it is still in clinical trials. Competitors include therapies that manage the symptoms of HD.
Market Dynamics
Industry Overview
The biopharmaceutical industry focused on brain diseases is characterized by high unmet needs, significant research and development investments, and regulatory complexities.
Positioning
Neumora is positioned as a company focused on precision medicine in neuroscience, aiming to develop targeted therapies for specific patient populations. Its competitive advantage lies in its novel drug candidates and biomarker-driven approach.
Total Addressable Market (TAM)
The TAM for brain disease therapeutics is substantial, estimated to be in the tens of billions of dollars annually. Neumora is targeting specific segments within this market with its pipeline of drug candidates. The market for MDD, SAD, and HD are all significant markets in their own right.
Upturn SWOT Analysis
Strengths
- Strong pipeline of novel drug candidates
- Focus on precision medicine
- Experienced management team
- Proprietary platform for target discovery
Weaknesses
- Dependence on clinical trial outcomes
- High cash burn rate
- Limited commercialization experience
- Concentrated pipeline risk
Opportunities
- Positive clinical trial results
- Partnerships with pharmaceutical companies
- Expansion into new indications
- Advancements in biomarker technology
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established pharmaceutical companies
- Patent challenges
Competitors and Market Share
Key Competitors
- LLY
- ABBV
- MRK
Competitive Landscape
Neumora competes with established pharmaceutical companies and other biotech firms developing therapies for brain diseases. Its advantages lie in its targeted approach and novel drug candidates, while its disadvantages include limited resources and commercialization experience.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by R&D progress and financial milestones related to funding and clinical trial initiations.
Future Projections: Future growth depends on successful clinical trial outcomes, regulatory approvals, and commercialization. Analyst estimates are speculative and depend on trial success.
Recent Initiatives: Recent initiatives include advancing Navacaprant into Phase 3 trials, progressing NMRA-266 into Phase 1 trials, and continuing to invest in its discovery platform.
Summary
Neumora Therapeutics is a clinical-stage biotech company with a promising pipeline focused on brain diseases. Its strength lies in its targeted therapies and novel drug candidates, but it faces risks associated with clinical trial outcomes and competition from larger pharmaceutical companies. Successful clinical trials and strategic partnerships are crucial for its future growth. The company needs to watch out for high cash burn and potential clinical trial failures.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Neumora Therapeutics, Inc. Investor Relations
- SEC Filings
- Industry Reports
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Neumora Therapeutics, Inc.
Exchange NASDAQ | Headquaters Watertown, MA, United States | ||
IPO Launch date 2023-09-14 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 96 | Website https://www.neumoratx.com |
Full time employees 96 | Website https://www.neumoratx.com | ||
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease. In addition, the company's preclinical phase product includes NMRA-NMDA and NMRA-M4R for the treatment of Schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.